RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+17.63%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.7B
AUM Growth
+$1.7B
(+2.6%)
Cap. Flow
-$115M
Cap. Flow
% of AUM
-6.77%
Top 10 Holdings %
Top 10 Hldgs %
43.98%
Holding
67
New
4
Increased
4
Reduced
33
Closed
4
Top Buys
| 1 |
BioNTech
BNTX
|
$18.3M |
| 2 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$10.1M |
| 3 |
Astria Therapeutics
ATXS
|
$3.42M |
| 4 |
Regenxbio
RGNX
|
$3.39M |
| 5 |
Penumbra
PEN
|
$2.69M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$38.4M |
| 2 |
Amicus Therapeutics
FOLD
|
$25.1M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$8.8M |
| 5 |
Replimune Group
REPL
|
$8.56M |
Sector Composition
| 1 | Healthcare | 97.73% |
| 2 | Industrials | 2.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$4.27B
| $147M | 8.69% | 810,245 -210,833 | -21% | -$38.4M |
|
2
Nurix Therapeutics
NRIX
$714M
| $96.2M | 5.67% | 4,280,981 -142,635 | -3% | -$3.21M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $88.1M | 5.19% | 8,246,592 -2,348,497 | -22% | -$25.1M |
|
4
Immunome
IMNM
$828M
| $71.5M | 4.21% | 4,889,554 | – | – |
|
|
5
Kymera Therapeutics
KYMR
$2.95B
| $65.9M | 3.88% | 1,393,256 -186,019 | -12% | -$8.8M |
|
6
Zymeworks
ZYME
$1.12B
| $64M | 3.77% | 5,101,911 -109,126 | -2% | -$1.37M |
|
7
Stoke Therapeutics
STOK
$1.08B
| $57.9M | 3.41% | 4,713,509 -7,545 | -0.2% | -$92.7K |
|
|
8
Replimune Group
REPL
$422M
| $52.4M | 3.09% | 4,781,183 -780,913 | -14% | -$8.56M |
|
9
Biohaven
BHVN
$1.63B
| $51.7M | 3.04% | 1,034,219 -53,357 | -5% | -$2.67M |
|
|
10
Regenxbio
RGNX
$451M
| $51.3M | 3.02% | 4,892,902 +323,100 | +7% | +$3.39M |
|
|
IGMS
11
DELISTED
IGM Biosciences
IGMS
| $50.8M | 2.99% | 3,072,478 | – | – |
|
12
ADC Therapeutics
ADCT
$345M
| $49.4M | 2.91% | 15,669,217 +400,000 | +3% | +$1.26M |
|
13
Cogent Biosciences
COGT
$1.69B
| $48.4M | 2.85% | 4,484,380 -315,593 | -7% | -$3.41M |
|
14
Fate Therapeutics
FATE
$120M
| $46.1M | 2.72% | 13,169,057 | – | – |
|
15
LivaNova
LIVN
$3.08B
| $46M | 2.71% | 875,039 -54,467 | -6% | -$2.86M |
|
16
Scholar Rock
SRRK
$3.14B
| $42M | 2.47% | 5,238,837 -214,246 | -4% | -$1.72M |
|
17
Neurogene
NGNE
$264M
| $40.5M | 2.38% | 964,347 -49,316 | -5% | -$2.07M |
|
18
Akero Therapeutics
AKRO
$3.74B
| $39.8M | 2.35% | 1,387,479 -226,994 | -14% | -$6.51M |
|
19
Beam Therapeutics
BEAM
$1.66B
| $39.5M | 2.33% | 1,611,013 -92,048 | -5% | -$2.26M |
|
|
AUGX
20
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $38.5M | 2.27% | 16,380,327 | – | – |
|
21
Annexon
ANNX
$226M
| $38.1M | 2.24% | 6,427,462 | – | – |
|
|
CTLT
22
DELISTED
CATALENT, INC.
CTLT
| $36.1M | 2.13% | 595,570 | – | – |
|
23
Pliant Therapeutics
PLRX
$101M
| $35.8M | 2.11% | 3,197,491 -12,100 | -0.4% | -$136K |
|
|
SLN
24
Silence Therapeutics
SLN
$227M
| $34.5M | 2.03% | 1,899,317 -114,979 | -6% | -$2.09M |
|
25
Keros Therapeutics
KROS
$618M
| $32.1M | 1.89% | 552,506 | – | – |
|